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Interleukin‐4 and interleukin‐13 evoke scratching behaviour in 
mice
Abstract
Persistent	 and	 relapsing	 itch	 commonly	manifests	 in	 inflammatory	








injecting	high	doses	 (2.5	ug/ml)	of	 IL‐4	and	IL‐13	 into	mice.	Similar	
experiments	in	our	lab,	however,	suggested	that	both	IL‐4	and	IL‐13	
contribute	 to	 acute	 itch	 in	 vivo.	We	 intradermally	 injected	 lower	





rapid	and	significant	 increase	of	scratching	after	 intradermal	 injec‐
tion	 of	 IL‐4,	 IL‐13	 or	 combined	 IL‐4/	 IL‐13	 compared	 to	 vehicle	 in	






Molecular	 cross‐talk	 between	 the	 immune	 system	 and	 the	 ner‐
vous	system	elicits	evolutionary	responses	such	as	itch	(pruritus)	to	
protect	 the	 host	 from	potential	 pathogens.[1,2]	 This	 neuroimmune,	






In	 March	 2017,	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 ap‐
proved	 a	 human	 anti‐interleukin‐4	 receptor	 alpha	 (IL‐4Rα)	 mono‐
clonal	 antibody	 known	 as	 Dupilumab/Dupixent	 for	 the	 treatment	
of	moderate‐to‐severe	AD.[7]	Dupilumab	targets	the	IL‐4Rα	subunit	
of	 IL‐4	 type	 I	and	 IL‐13	type	 II	 specific	 receptor	complexes.[8]	This	
leads	to	inhibition	of	the	JAK‐STAT	signalling	pathway	known	to	par‐
ticipate	 in	 AD	 pathophysiology.[9]	 After	 subcutaneous	 injection	 of	
Dupilumab	once	a	week	for	12	weeks,	AD	symptoms	were	reduced	









to	the	researchers’	hypothesis;	 “Based	on	our	 findings	that	 type	2	
cytokines	directly	 activate	 itch	 sensory	neurons,	we	hypothesized	
















Scratching	 behaviour	 analysis	 was	 carried	 out	 in	 a	 blinded	 fash‐
ion.	 After	 injection	 of	 rmIL‐4,	 there	 was	 a	 significant	 increase	 of	
scratching	 bouts	 compared	with	 vehicle	 and	 an	 overall	 significant	
effect	of	treatment	(P	<	 .0001)	(Figure	1A).	rmIL‐13	also	induced	a	
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significant	 increase	of	scratching	compared	with	vehicle	 (P	<	 .001)	
(Figure	1B).	After	injection	of	the	combination	treatment	rmIL‐4	and	
rmIL‐13,	 there	 was	 a	 significant	 increase	 of	 scratching	 compared	
with	vehicle	(P	<	.0001).	Interestingly,	the	combination	treatment	of	
rmIL‐4	and	rmIL‐13	produced	acute	pruritus	at	an	earlier	time	point	
than	 the	 two	treatments	administered	alone	 (Figure	1C).	Two‐way	
ANOVA	 Bonferroni's	 multiple	 comparison	 test	 indicated	 a	 signifi‐
cant	 increase	of	 scratching	bouts	 in	mice	 i.d.	 injected	with	 rmIL‐4	
at	10	minutes	(P	<	.001)	and	15	minutes	(P	<	.01),	rmIL‐13	at	10	min‐
utes	 (P	<	 .05)	and	rmIL‐4	and	rmIL‐13	 in	combination	at	5	minutes	
(P	<	.0001)	and	10	minutes	(P	<	.0001).	The	combined	activation	of	
IL‐4	 type	 I	 and	 IL‐13	 type	 II	 specific	 receptor	complexes	could	ac‐
count	 for	 the	marked	 increase	 in	 acute	 pruritus.	 rmIL‐4	 showed	 a	
similar	 scratching	 behaviour	 profile	 to	 the	 positive	 control	 group,	
histamine	(Figure	2).
5  | CONCLUSIONS
Our	 results	 show	 that	 IL‐4	 and	 IL‐13	 produce	 a	 direct,	 acute	 pru‐
ritic	 effect	 immediately	 after	 intradermal	 injection	 in	 mice.	 Our	
data	show	comparable	direct	acute	effects	of	 IL‐4	and	 ‐13,	as	ob‐
served	for	IL‐31	which	is	considered	as	a	direct	acute	pruritogen	in	




























































unexpected	high	number	of	 scratching	bouts	 (approx.	25	bouts	 in	
30	minutes)	similar	to	treatment	groups.	As	a	result,	their	study	finds	
no	 significant	 difference	 of	 scratching	 between	 vehicle	 and	 treat‐
ment.	 Second,	 a	 possible	 explanation	 for	 disparity	 could	 be	 that	
Oetjen	 et	 al[11]	 used	 2.5	 µg	 rmIL‐4	 and	 2.5	 µg	 rmIL‐13	 treatment	
concentrations.	 Maintaining	 equilibrium,	 higher	 concentrations	 in	
healthy	mice	could	stimulate	negative	feedback	regulation.	Negative	
feedback	 dysregulation	 of	 the	 JAK‐STAT	 pathway	 has	 been	 impli‐
cated	in	inflammatory	diseases.[14]	Suppressor	of	cytokine	signalling	







tors,	 stimulating	 the	 expression	 of	 SOCS1,	 SOCS5	 and	 IL‐13Rα2,	
inhibiting	 JAK‐STAT	 signalling	of	 IL‐4	 type	 I	 and	 type	 II	 receptors,	
blocking	 the	 activation	 of	 sensory	 neurons	 and	 in	 turn,	 produc‐
ing	a	 lower	scratch	response	compared	with	lower	concentrations.	
Interestingly,	 the	 combined	 treatment	 of	 IL‐4	 and	 IL‐13	 produced	





















independently	 and	 exert	 an	 additional	 effect	when	 applied	 simul‐
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